# Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines

> **NCT05801146** · PHASE3 · UNKNOWN · sponsor: **Hugel** · enrollment: 272 (estimated)

## Conditions studied

- Glabellar Lines

## Interventions

- **DRUG:** Botulinum Toxin Type A Injection [HG102]
- **DRUG:** Botulinum Toxin Type A Injection [Botox]

## Key facts

- **NCT ID:** NCT05801146
- **Lead sponsor:** Hugel
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-04
- **Primary completion:** 2025-03
- **Final completion:** 2025-10
- **Target enrollment:** 272 (ESTIMATED)
- **Last updated:** 2024-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05801146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05801146, "Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05801146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*